97682-44-5|Irinotecan
Irinotecan prevents DNA from unwinding by inhibition of topoisomerase 1. In chemical terms, it is a semisynthetic analogue of the natural alkaloid camptothecin.
Its main use is in colon cancer, in particular, in combination with other chemotherapy agents. This includes the regimen FOLFIRI, which consists of infusional 5-fluorouracil, leucovorin, and irinotecan.
Irinotecan received accelerated approval by the U.S. Food and Drug Administration (FDA) in 1996 and full approval in 1998. During development, it was known as CPT-11.
7-ethoxyxanthone-3-carboxylic acid;
9H-Xanthene-3-carboxylic acid,7-ethoxy-9-oxo;
CAS 97682-44-5|Irinotecan
|
97682-44-5 |
|
|
C33H38N4O6 |
|
|
586.68 |
|
|
691-567-9 |
|
|
222-223 degree |
|
|
873.4±65.0 degree (Predicted) |
|
|
1.40±0.1 g/cm3(Predicted) |
P 97682-44-5|Irinotecan
Package:0.1g,1g,5g,25g,100g,500g,1kg
of CAS 97682-44-5|Irinotecan
Irinotecan: 25 years of cancer treatment
C Bailly - Pharmacological research, 2019 - Elsevier
… Structure and conformation of irinotecan (IRT). The main enzymes implicated in the … 2019
marks the 25 th anniversary of the medical use of the drug irinotecan (Campto®, Camptosar®), …
Popularni tagovi: cas:97682-44-5|irinotecan, China cas:97682-44-5|irinotecan manufacturers, factory
